Edesa Biotech Inc EDSA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.14 up $0.01, 0.47% at close Nov 6
Last close · Previous close $2.13
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.69Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.14down $1.58, 42.47%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.13Nov 5
- Volume37.77KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume46.77KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.72 to $20.32; now $2.14
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
EDSA beat the S&P 500 in 2 of 7 periods.
| Period | EDSA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EDSA: down 42.5% S&P 500: down 5.6% | EDSA trailed the S&P 500 by 36.9 percentage points Trailed |
| 3M | EDSA: down 57.6% S&P 500: down 4.1% | EDSA trailed the S&P 500 by 53.5 percentage points Trailed |
| YTD | EDSA: up 50.7% S&P 500: up 8.7% | EDSA beat the S&P 500 by 42.0 percentage points Beat |
| 1Y | EDSA: up 25.9% S&P 500: up 10.9% | EDSA beat the S&P 500 by 15.0 percentage points Beat |
| Long term | ||
| 3Y | EDSA: down 35.0% S&P 500: up 75.0% −13.4% vs +20.5% a year | EDSA trailed the S&P 500 by 110.0 percentage points Trailed |
| 5Y | EDSA: down 96.0% S&P 500: up 67.8% −47.4% vs +10.9% a year | EDSA trailed the S&P 500 by 163.8 percentage points Trailed |
| 10Y | EDSA: down 99.6% S&P 500: up 313.1% −43.0% vs +15.2% a year | EDSA trailed the S&P 500 by 412.7 percentage points Trailed |
$10,000 invested in EDSA 10 years ago (Nov 4, 2016) would be worth about $36 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
EDSA beat the S&P 500 in 2 of 7 periods.
| Period | EDSA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EDSA: down 42.5% S&P 500: down 5.6% | EDSA trailed the S&P 500 by 36.9 percentage points Trailed |
| 3M | EDSA: down 57.6% S&P 500: down 4.3% | EDSA trailed the S&P 500 by 53.3 percentage points Trailed |
| YTD | EDSA: up 50.7% S&P 500: up 7.8% | EDSA beat the S&P 500 by 42.9 percentage points Beat |
| 1Y | EDSA: up 25.9% S&P 500: up 9.7% | EDSA beat the S&P 500 by 16.2 percentage points Beat |
| Long term | ||
| 3Y | EDSA: down 35.0% S&P 500: up 68.8% −13.4% vs +19.1% a year | EDSA trailed the S&P 500 by 103.8 percentage points Trailed |
| 5Y | EDSA: down 96.0% S&P 500: up 56.9% −47.4% vs +9.4% a year | EDSA trailed the S&P 500 by 152.9 percentage points Trailed |
| 10Y | EDSA: down 99.6% S&P 500: up 252.6% −43.0% vs +13.4% a year | EDSA trailed the S&P 500 by 352.2 percentage points Trailed |
$10,000 invested in EDSA 10 years ago (Nov 4, 2016) would be worth about $36 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$2,766.54
Closing high on . Now 99.9% below that record.
Split-adjusted daily closes since Nov 5, 2015.
Stock splits
3
Latest: 1-for-7 on . Share counts adjust after each split.
All 3 splits
- 1-for-7
- 1-for-6
- 1-for-7
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$14.10M
- Diluted EPS
- −$1.69
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Sep 30, 2024) | $0.00 | −$962.05K | −$0.29 |
| Q1 FY25 (Dec 31, 2024) | $0.00 | −$1.62M | −$0.48 |
| Q2 FY25 (Mar 31, 2025) | $0.00 | −$1.59M | −$0.30 |
| Q3 FY25 (Jun 30, 2025) | $0.00 | −$1.75M | −$0.25 |
| Q4 FY25 (Sep 30, 2025) | $0.00 | −$2.23M | −$0.32 |
| Q1 FY26 (Dec 31, 2025) | $0.00 | −$2.25M | −$0.28 |
| Q2 FY26 (Mar 31, 2026) | $0.00 | −$4.22M | −$0.49 |
| Q3 FY26 (Jun 30, 2026) | $0.00 | −$5.41M | −$0.60 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Sep 30, 2021) | $0.00 | −$13.34M | Paused See the note under the price. |
| FY22 (Sep 30, 2022) | $0.00 | −$17.55M | Paused See the note under the price. |
| FY23 (Sep 30, 2023) | $0.00 | −$8.37M | Paused See the note under the price. |
| FY24 (Sep 30, 2024) | $0.00 | −$6.17M | −$1.93 |
| FY25 (Sep 30, 2025) | $0.00 | −$7.19M | −$1.27 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$8.91MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$8.91MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $6.98MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $10.37MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$10.37MAs of Jun 30, 2026
- 2.76As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −124.2%Last 12 months
Over the last 12 months, Edesa Biotech lost money: its net loss was 124.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −105.7%Last 12 months
Over the last 12 months, Edesa Biotech’s net loss was 105.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Edesa Biotech Inc
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts. Connect with us on X and LinkedIn.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Ontario, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
EDSA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
EDSA stock FAQ
What is EDSA stock’s price today?
Edesa Biotech (EDSA) traded at $2.14 at the close on , up $0.01 (0.47%) from the previous close of $2.13. Over the past 52 weeks it has traded between $0.72 and $20.32.
If you invested $1,000 in EDSA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in EDSA on would be worth about $4 at the close on , a total return of −99.6%. The same $1,000 would be worth $40 if invested five years ago and $1,259 if invested one year ago. Past performance doesn’t predict future returns.
What is EDSA’s P/E ratio?
EDSA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.69).
What are EDSA’s earnings per share?
EDSA’s diluted earnings per share were −$1.69 over the four quarters to , compared with −$1.32 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.60 per share, against −$0.25 a year earlier (how EPS works).
Does EDSA pay a dividend?
Edesa Biotech hasn’t paid a dividend in the last twelve months.
What is EDSA’s 52-week high and low?
Over the past 52 weeks EDSA has traded as low as $0.72 and as high as $20.32. At $2.14 at the close on , it is 89.5% below that high and 197.2% above the low.
What is EDSA’s all-time high?
EDSA’s highest closing price was $2,766.54 on , adjusted for stock splits. At $2.14 at the close on , it is 99.9% below that record.
Has EDSA stock ever split?
Yes, three times: 1-for-7 on ; 1-for-6 on ; 1-for-7 on .
How has EDSA stock performed?
Including dividends and measured to the close on , EDSA has returned +50.7% so far this year and +25.9% over the past year, and −96.0% over five years (−47.4% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Edesa Biotech in?
Edesa Biotech is in the Healthcare sector and the Biotechnology industry, and is headquartered in Ontario, Canada.
What exchange does EDSA trade on?
Edesa Biotech trades on the Nasdaq under the ticker symbol EDSA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.